5 recruiting, 4 not yet recruiting, 2 active not recruiting, 2 completed. 9 Phase 1, 7 Phase 2, 2 Not applicable.
Follow RCC: new trials by email Literature Review of RCC trials Research Report on RCC
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Multicenter Randomized Open-Label Trial Evaluating ctDNA-Guided Interruption Versus Standard of Care Immune-Checkpoint Inhibitor (ICI) Therapy In Patients With Advanced / Metastatic Solid Tumors. Signatera Genome ultra-sensitive ctDNA blood test - NSCLC (Advanced Non-small Cell Lung Cancer), NSCLC (Non-small Cell Lung Cancer) | Not applicable | Not yet recruiting | Natera, Inc. | 920 | 2026-12-01 | 2026-08-04 |
| A Multicenter Real-World Study on TKI Therapy After Progression on First-Line TKI/IO Therapy or TKI/IO Therapy After Progression on First-Line TKI in Chinese Patients With Metastatic Renal Cell Carcinoma (mRCC) RCC | Not yet recruiting | Tianjin Medical University Cancer Institute and Hospital | 860 | 2025-12-31 | 2026-01-08 | |
| Open-Label Phase 1/2 Study of NEO-811 in Subjects With Locally Advanced or Metastatic Non-Resectable Clear Cell Renal Cell Carcinoma NEO-811 - Clear Cell Renal Cell Carcinoma, Renal Cell Carcinoma | Phase 1 | Recruiting | Neomorph, Inc | 30 | 2025-12-19 | 2026-10-05 |
| A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression A2B395, xT CDx with HLA-LOH assay - Solid Tumor, Adult, Colorectal Cancer | Phase 1 / Phase 2 | Recruiting | A2 Biotherapeutics Inc. | 240 | 2025-05-22 | 2025-09-09 |
| A Prospective Registry Study of Stereotactic Ablative Radiotherapy (SABR) for Oligometastatic/Oligometastatic Renal Cell Carcinoma Stereotactic Ablative Radiotherapy (SABR) - Renal Cell Carcinoma, RCC | Not applicable | Not yet recruiting | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 60 | 2024-09-01 | 2024-09-19 |
| Vorolanib Combined With Cadonilimab in the Treatment of Untreated Advanced RCC Patients Vorolanib, cadonilimab - Kidney Cancer, RCC | Phase 1 / Phase 2 | Not yet recruiting | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 37 | 2024-08-31 | 2024-08-29 |
| A Study of SPX-303, a Bispecific Antibody Targeting LILRB2 and PD-L1 in Patients With Solid Tumors SPX- 303 Injection, a bispecific anti-LILRB2 / anti-PD-L1 Antibody - Solid Tumor, HNSCC | Phase 1 | Recruiting | SparX Biotech(Jiangsu) Co., Ltd. | 232 | 2024-03-20 | 2024-09-24 |
| Sequential Treatment of Cabozantinib for Advanced Renal Cell Carcinoma (RCC) Cabozantinib 80 MG - RCC, Renal Cell Carcinoma | Phase 2 | Recruiting | University of Texas Southwestern Medical Center | 18 | 2023-12-20 | 2026-10-23 |
| Renal Cancer Monitoring Based on ctDNA Methylomics: A Prospective Cohort Study (MEMORY Study) Carcinoma, Renal Cell Carcinoma | Recruiting | Jinling Hospital, China | 450 | 2022-12-26 | 2025-12-11 | |
| Study of CB-839 (Telaglenastat) in Combination With Talazoparib in Patients With Solid Tumors CB-839, Talazoparib - Solid Tumor, Clear Cell Renal Cell Carcinoma | Phase 1 / Phase 2 | Terminated | Calithera Biosciences, Inc | 33 | 2019-05-20 | 2022-02-17 |
| A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies INCAGN02390 - Cervical Cancer, Gastric Cancer | Phase 1 | Completed | Incyte Corporation | 40 | 2018-09-24 | 2021-11-15 |
| Sunitinib Followed by Avelumab or the Reverse for Metastatic Renal Cell Carcinoma Avelumab, Sunitinib - Clear-cell Renal Cell Carcinoma, RCC | Phase 2 | Withdrawn | Guru Sonpavde | 2017-05-23 | 2022-02-15 | |
| A Trial of Belzutifan (PT2977, MK-6482) Tablets In Patients With Advanced Solid Tumors (MK-6482-001) Belzutifan - Advanced Solid Tumors, Solid Tumor | Phase 1 | Active not recruiting | Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 120 | 2016-12-07 | 2026-10-26 |
| Nivolumab in mRCC Patients: Treg Function, T-cell Access and NK Interactions to Predict and Improve Efficacy Immunological and tumour characterization - RCC, Metastatic Renal Cell Carcinoma | Completed | National Cancer Institute, Naples | 200 | 2016-12-01 | 2025-03-11 | |
| Study of Ixazomib With Pegylated IFN-alpha 2b (pIFN) in Metastatic Renal Cell Carcinoma (mRCC) Ixazomib, Pegylated IFN-alpha 2b - Metastatic Renal Cell Carcinoma, RCC | Phase 1 / Phase 2 | Terminated | Fox Chase Cancer Center | 3 | 2015-08-14 | 2019-09-26 |
| A Phase 1, Dose-Escalation Trial of PT2385 Tablets In Patients With Advanced Clear Cell Renal Cell Carcinoma (MK-3795-001) MK-3795, Nivolumab, Cabozantinib - ccRCC, RCC | Phase 1 | Active not recruiting | Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 110 | 2014-11-25 | 2024-06-17 |
| Phase II Study of Anlotinib Versus Sunitinib in Patients With Advanced Renal Cell Carcinoma（RCC） Anlotinib, Sunitinib maleate - Anlotinib, RCC | Phase 2 | Unknown | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 133 | 2013-12-01 | 2016-04-26 |
Carcinoma, Renal Cell (14) · Kidney Neoplasms (8) · Carcinoma, Non-Small-Cell Lung (3) · Colorectal Neoplasms (3) · Squamous Cell Carcinoma of Head and Neck (3) · Triple Negative Breast Neoplasms (3) · Melanoma (2) · Carcinoma (1) · Carcinoma, Hepatocellular (1) · Carcinoma, Merkel Cell (1) · Carcinoma, Transitional Cell (1) · Clear-cell metastatic renal cell carcinoma (1) · Colonic Neoplasms (1) · Esophageal Neoplasms (1) · Glioblastoma (1)
Neoplasms by Histologic Type (15) · Neoplasms by Site (15) · Neoplasms, Glandular and Epithelial (15) · Adenocarcinoma (14) · Carcinoma (14) · Female Urogenital Diseases (14) · Female Urogenital Diseases and Pregnancy Complications (14) · Kidney Diseases (14) · Male Urogenital Diseases (14) · Neoplasms (14) · Urogenital Diseases (14) · Urogenital Neoplasms (14) · Urologic Diseases (14) · Urologic Neoplasms (14) · Kidney Neoplasms (6)
Sunitinib (2) · belzutifan (2) · cabozantinib (2) · CB-839 (1) · Nivolumab (1) · PT2385 (1) · anlotinib (1) · avelumab (1) · endothelial PAS domain-containing protein 1 (1) · ixazomib (1) · talazoparib (1) · vorolanib (1)
Cancer Institute and Hospital, Chinese Academy of Medical Sciences (2) · Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) (2) · A2 Biotherapeutics Inc. (1) · Calithera Biosciences, Inc (1) · Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (1) · Fox Chase Cancer Center (1) · Guru Sonpavde (1) · Incyte Corporation (1) · Jinling Hospital, China (1) · Natera, Inc. (1) · National Cancer Institute, Naples (1) · Neomorph, Inc (1) · SparX Biotech(Jiangsu) Co., Ltd. (1) · Tianjin Medical University Cancer Institute and Hospital (1) · University of Texas Southwestern Medical Center (1)
United States (9) · China (3) · Italy (1)
Caitlin Shonewolf, MD (1) · Guidong Zhu (1) · Guru Sonpavde, M.D. (1) · John Welch, MD, PhD (1) · Klaus Wagner, MD, PhD (1) · Nawel Bourayou, MD (1) · Sam Whiting, MD, PhD (1) · Tian Zhang, MD (1)